Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting
EMERYVILLE, Calif., Sept. 3 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that new research data will be delivered as an oral presentation during the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA on September 13, 2009. The presentation will describe results from a multi-institutional collaborative in vitro study of Adamas' triple combination antiviral drug (TCAD) therapy.
Presentation details: Title: Triple Combination of Amantadine, Ribavirin and Oseltamivir Restores In Vitro Activity of Antiviral Drugs against Resistant Influenza Viruses Date/Time: Sunday, Sep 13, 2009, 10:45 AM -11:00 AM Session: 064-Respiratory Viruses and Influenza Sunday, Sep 13, 2009, 8:30 AM -11:00 AM Abstract Number: V-537b Location: Marriott Salon 9 Authors: J. T. NGUYEN (1), J. HOOPES (2), D. SMEE (2), M. LE (1), A. PATICK (1), M. DE JONG (3), G. WENT (1), D. FAIX (4), P. BLAIR (4), M. PRICHARD (5); (1) Adamas Pharmaceuticals, Emeryville, CA, (2) Utah State Univ., Logan, UT, (3) Amsterdam Med. Ctr., Amsterdam, Netherlands, (4) Naval Health Research Center, San Diego, CA, (5) Univ. of Alabama, Birmingham, AL.
Adamas is pioneering triple-combination antiviral drug (TCAD) therapy for influenza, which is designed to inhibit viral replication at multiple points during the virus life cycle. TCAD therapy includes Adamas' investigational proprietary fixed-dose combination of amantadine and ribavirin, to be administered adjunctively with a neuraminidase inhibitor such as Tamiflu (oseltamivir phosphate, Roche). Preclinical data indicate that the in vitro combination of these drugs, each with their own mechanism of action, acts synergistically to provide a much higher level of antiviral activity than single or double drug combinations. In in vitro studies to date, TCAD therapy also has been found to provide greater antiviral activity across multiple strains of influenza, even those resistant to single pharmaceutical agents. Adamas is accelerating development of its TCAD therapy for influenza A by conducting a Phase 2 clinical trial in the Southern Hemisphere where the novel influenza A/H1N1 pandemic is active, and is preparing to initiate a clinical study of TCAD therapy for influenza A in North America during this upcoming flu season.
Adamas is an emerging pharmaceutical company focused on developing small molecule, Advantaged Therapeutics(TM) to treat neurological and infectious diseases, including influenza A, the cause of the current flu pandemic. Adamas' approach to pharmaceutical development is to identify synergistic drug mechanisms that can be developed as optimized combination drug therapies to increase safety, efficacy and compliance, thus improving upon the standard of care. Adamas is headquartered in Emeryville, California, with operations in Bangalore, India. For more information about Adamas, please visit www.adamaspharma.com.
SOURCE Adamas Pharmaceuticals, Inc.